BioLineRx sells APHEXDA royalty rights for $5.6 million

BioLineRx (BLRX) sold 14.4% royalty rights to APHEXDA for $5.6M to Soleus Capital. The deal excludes 3.6% royalties. Proceeds will fund R&D, working capital, and partial loan repayment. The transaction is expected to close by November 30, 2026. APHEXDA is an FDA-approved drug for stem cell mobilization in multiple myeloma. BioLineRx is also developing GLIX1 for glioblastoma.

Original reporting
Published Nov 18, 2026, 12:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$BLRX
Neutral
medium confidence
Mentioned
$BLRX
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BLRXNeutralMed
01

Why it matters

The transaction converts a portion of future royalty receipts into upfront cash, intended to fund GLIX1 clinical development and working capital, and it removes a $4 million minimum cash balance requirement under a related loan agreement.

02

Market read

Traders may reassess BioLineRx’s near-term liquidity, debt covenant flexibility, and the trade-off between upfront funding and reduced future royalty participation.

03

What to watch

The article notes BioLineRx retains milestone payments and pre-closing royalties, so the net economic impact depends on expected future sales trajectory and the remaining 3.6% royalty exclusion mechanics.

Relevance 6/10Novelty 7/10Timing: expected close on or about Nov 30, 2026

Background

BioLineRx has a royalty interest in APHEXDA under an existing license agreement with Ayrmid Pharma; APHEXDA is FDA-approved for mobilizing hematopoietic stem cells in multiple myeloma.

Company-level read

Ticker impact

$BLRXNeutralMedium confidence
Context

BioLineRx will sell its 14.4% APHEXDA royalty interest for a one-time $5.6 million, shifting future cash flows and funding R&D.

Expected impact

Likely modest positive bias on liquidity, partially offset by reduced future royalty economics.

Evidence & confidence

The deal is specific (14.4% interest, $5.6M, closing around Nov 30, 2026) and tied to stated use of proceeds, but it is not a full exit and the amount is relatively small versus typical biotech valuations.

Market effects

Highlights a broader biotech financing pattern of monetizing royalty streams to fund clinical programs.

Limited direct regional spillover; transaction is company-specific and tied to a US-approved product.

APHEXDA commercialization is global (with Asia partnership), but the news mainly affects BioLineRx’s capital structure and cash-flow profile.

Counterpoint

The $5.6M monetization could be viewed as selling upside too cheaply if APHEXDA royalty economics improve materially after commercialization ramps.

Key entities

  • BioLineRx Ltd.

    NASDAQ-listed biotech selling part of its APHEXDA royalty rights to Soleus Capital for $5.6M.

  • Soleus Capital Management, L.P.

    Acquirer of BioLineRx’s 14.4% royalty interest in future net sales of APHEXDA.

  • APHEXDA

    FDA-approved CXCR4 antagonist used with filgrastim for stem cell mobilization in multiple myeloma.

  • Ayrmid Pharma Ltd.

    Holds the existing license agreement under which APHEXDA royalties are owed to BioLineRx.

  • GLIX1

    BioLineRx Phase 1/2a glioblastoma and other solid tumors program currently enrolling the fourth of five dosing cohorts.

Related articles

$BLRXLow

BioLineRx initiates fourth cohort in GLIX1 brain tumor trial

BioLineRx and Hemispherian started the fourth cohort of a Phase 1/2a trial for GLIX1, a treatment for high-grade glioma. The study showed no significant adverse events. Preclinical data indicated tumor eradication and growth inhibition. BioLineRx expects results in early 2027. According to the companies, GLIX1 demonstrated brain penetration and biological activity.

$BLRXMedAI 8/10

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026

BioLineRx (BLRX) and Hemispherian presented Phase 1/2a clinical study and pre-clinical updates for GLIX1 at the SNO 2026 Annual Meeting. The study, ongoing with no safety concerns, includes a fourth cohort and plans for window-of-opportunity cohorts. GLIX1 showed robust, dose-dependent antitumor activity in multiple glioblastoma models, including brain penetration and dose-dependent increases in tumor 5hmC.

$BLRXMedAI 8/10

BioLineRx, Hemispherian report GLIX1 data at ESMO 2026

BioLineRx (BLRX) and Hemispherian presented preclinical data at ESMO 2026, showing GLIX1's synergy with PARP inhibitors in HR-proficient ovarian cancer models. The combination demonstrated significant tumor growth inhibition. GLIX1 is in a Phase 1/2a trial for glioblastoma, with plans to add an ovarian cancer arm. According to the companies, the data suggest GLIX1 could expand PARP inhibitors' activity to HR-proficient tumors.

$BLRXLowAI 8/10

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026

BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1's synergy with PARP inhibitors in HR-proficient ovarian cancer. GLIX1, a TET2 activator, demonstrated tumor growth inhibition in combination with olaparib, veliparib, and niraparib. BioLineRx plans to add an ovarian cancer arm to its ongoing Phase 1/2a trial for glioblastoma.

$BLRXMedAI 8/10

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

BioLineRx (BLRX) and Hemispherian AS announced preclinical data and trial design for GLIX1, a TET2 activator, will be presented at EANO 2026. GLIX1 showed anti-tumor activity in glioblastoma models, with a Phase 1/2a trial actively enrolling patients. BioLineRx is developing GLIX1 for glioblastoma and other solid tumors.